Navigation Links
Cleveland Clinic selected to participate in National MDS Clinical Research Consortium
Date:6/7/2012

Thursday, June 7, 2012, Cleveland: Taussig Cancer Institute at Cleveland Clinic will participate in an unprecedented, six-institution consortium designed to conduct clinical trials and research to improve outcomes for patients with myelodysplastic syndrome (MDS). Known as the MDS Clinical Research Consortium, the five-year, $16 million initiative is sponsored by the Aplastic Anemia & MDS International Foundation and supported by the Edward P. Evans Foundation.

This is the first privately funded MDS research consortium in the U.S. Mikkael Sekeres, M.D., M.S., Director of Taussig Cancer Institute's Leukemia Program, will co-chair the Consortium with Guillermo Garcia-Manero, M.D. of MD Anderson Cancer Center. The Consortium will fill a major gap in MDS-related clinical research by providing a new "critical mass" of dedicated institutions to support the evaluation of promising new therapies, epidemiological studies, and translational studies leading to new treatments and classifications for these diseases. It will also sponsor a yearly, dedicated MDS fellowship slot at each institution.

Centralized clinical operations (data collection and management, biostatistics, clinical trial accrual and supervision of research protocols) will be housed at Taussig Cancer Institute. The Consortium will be administered by the Aplastic Anemia & MDS International Foundation.

"This Consortium is the first clinical research network created to support the infrastructure that makes MDS clinical research happen by enabling the collaboration of the leading MDS centers is the U.S.," said Dr. Sekeres.

The other five participating institutions include Dana Farber Cancer Institute; MD Anderson Cancer Center; H. Lee Moffitt Cancer Center and Research Institute; Weill Medical College of Cornell University; and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

"One of the greatest challenges in research of rare diseases like MDS is having enough patients to conduct meaningful clinical trials. No single center can do it alone. This uniquely collaborative effort overcomes that barrier," said John Huber, Executive Director of the Aplastic Anemia & MDS International Foundation. "To have these six leading MDS research centers working together in this way is unprecedented."

Programs selected as part of the Consortium are based at U.S. academic medical centers that serve a high volume of MDS patients; that maintain a current and historical patient data base; and that have a current and retrospective MDS patient cohort of sufficient size to have a very significant track record of participation in MDS-related clinical trials.

MDS is a cancer of hematopoietic bone marrow stem cells akin to leukemia that inhibits the body's ability to produce healthy blood cells. It principally affects adults over the age of 60 years, and can be treated with chemotherapy, growth factor, or immuonomodulatory therapies. At present, the only cure is a bone marrow transplant.


'/>"/>
Contact: Joe Milicia
milicij2@ccf.org
216-312-0591
Cleveland Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic, youth mental health experts, publish new guidelines to treat childhood aggression
2. Mayo Clinic Alzheimers researcher honored twice in a month
3. Mayo Clinic urologists present findings at American Urological Association Annual Meeting
4. Canada should significantly increase its funding of randomized clinical trials
5. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
6. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
7. Experts call for clinical trials to test non-skeletal benefits of vitamin D
8. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
9. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... 2017 , ... Medic CE , a Career Step company, is sponsoring ... hosted by the Journal of Emergency Medical Services (JEMS). The free webinar, to be ... by Captain Rommie Duckworth, LP, a career fire captain as well as founder and ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... prominent for-profit and nonprofit hospitals and health systems in the nation and help ... their institutions, led professional organizations and been instrumental in developing successful hospital and ...
(Date:5/23/2017)... ... , ... Axiad IDS , a leading provider of trusted identities for ... company a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this honor ... proactively address potential cybersecurity threats before they happen. The annual list of ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... and a 2017 Best in KLAS category winner, has named Daniel P. Bullington ... extend and enhance its technology platform and product offerings,” says Justin Neece, president. ...
(Date:5/23/2017)... ... May 23, 2017 , ... Drs. Allen Huang and Jeffrey ... in Las Vegas, NV, and the importance of treating it immediately. They are ... care for peri-implantitis, with or without a referral. As experienced periodontists and implant ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
(Date:5/6/2017)... , May 5, 2017   Provista , a ... more than 200,000 customers, today announced Jim Cunniff ... wealth of executive and business experience to Provista, including most ... pharmacy in California . He assumed his ... "Jim is a great fit for Provista," says Jody ...
Breaking Medicine Technology: